Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Outpatient supportive care following chemotherapy for acute myeloblastic leukemia
Autore:
Allan, DS; Buckstein, R; Imrie, KR;
Indirizzi:
Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada Toronto Sunnybrook Reg Canc Ctr Toronto ON Canada M4N 3M5 M4N 3M5, Canada
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 3, volume: 42, anno: 2001,
pagine: 339 - 346
SICI:
1042-8194(200107)42:3<339:OSCFCF>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; CONSOLIDATION CHEMOTHERAPY; PROMYELOCYTIC LEUKEMIA; INDUCTION; DAUNORUBICIN; NEUTROPENIA; CYTARABINE; THERAPY;
Keywords:
acute myeloid leukemia; treatment; outpatient; supportive care; adult;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Imrie, KR Toronto Sunnybrook Reg Canc Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada Toronto Sunnybrook Reg Canc Ctr 2075 Bayview Ave Toronto ON Canada M4N 3M5
Citazione:
D.S. Allan et al., "Outpatient supportive care following chemotherapy for acute myeloblastic leukemia", LEUK LYMPH, 42(3), 2001, pp. 339-346

Abstract

Treatment of acute myeloid leukemia (AML) involves aggressive myelosuppressive chemotherapy that is generally administered on an inpatient basis. In our centre, AML therapy has been initiated in hospital and followed by early outpatient supportive care according to guidelines established in 1996. We conducted a review of all patients presenting with AML in our centre between January 1996 and July 1998 to evaluate the safety and feasibility of early outpatient supportive care. Nineteen consecutive patients treated with induction chemotherapy were analyzed. Patients were treated with cytosine arabinoside and an anthracycline as aggressive AML induction therapy with the intent for early discharge. Ten patients (53%) were discharged within 10 days of starting induction chemotherapy (median 4.5 days). Reasons for remaining in hospital included sepsis, serious medical complications, and social and geographic factors. Patients discharged early had a median of 1.5 readmissions (range 0-3), but had 30% fewer in-hospital days than inpatients (p=0.03), and 57% fewer days of in-hospital antibiotic therapy (p=0.01). There were no significant differences in transfusion requirements or episodes of febrile neutropenia between the two groups. Thirty-one cycles of consolidation therapy were administered to the 18 patients who survived induction. Early discharge from hospital was achieved for 30 cycles (97%). Nine cycles of consolidation chemotherapy were delivered using outpatient intravenousinfusion pumps (29%). This study supports the feasibility and safety of early discharge and outpatient supportive care following chemotherapy for AML.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 07:42:20